Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis

TY - JOUR

T1 - Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis

AU - Simm, Peter J

AU - Johannesen, Jesper

AU - Briody, Julie

AU - McQuade, Mary

AU - Hsu, Brian

AU - Bridge, Corinne

AU - Little, David G

AU - Cowell, Christopher T

AU - Munns, Craig F

N1 - Crown Copyright © 2011. Published by Elsevier Inc. All rights reserved.

PY - 2011/11

Y1 - 2011/11

N2 - There are limited data on the use of bisphosphonate therapy for secondary osteoporoses in childhood, and no previous reports of the use of zoledronic acid in this group. We report 20 children with a variety of underlying primary diagnoses with associated secondary osteoporosis, who were treated with 3 monthly zoledronic acid for 2 years (annualised dose 0.1mg/kg/year). There was a significant improvement in lumbar spine (by 1.88 SD±1.24 over first 12 months, p

AB - There are limited data on the use of bisphosphonate therapy for secondary osteoporoses in childhood, and no previous reports of the use of zoledronic acid in this group. We report 20 children with a variety of underlying primary diagnoses with associated secondary osteoporosis, who were treated with 3 monthly zoledronic acid for 2 years (annualised dose 0.1mg/kg/year). There was a significant improvement in lumbar spine (by 1.88 SD±1.24 over first 12 months, p

U2 - 10.1016/j.bone.2011.07.031

DO - 10.1016/j.bone.2011.07.031

M3 - Journal article

SN - 8756-3282

VL - 49

SP - 939

EP - 943

JO - Bone

JF - Bone

IS - 5

ER -